Research Fellowship to Study Hiv Vaccines

Modeling of antilatency treatment in HIV: What is the optimal duration of antiretroviral therapy-free HIV remission?

D Cromer, M Pinkevych, TA Rasmussen, SR Lewin, SJ Kent, MP Davenport

2017-12-01

A number of treatment strategies are currently being developed to promote antiretroviral therapy-free HIV cure or remission. While..

Fc functional antibodies in humans with severe H7N9 and seasonal influenza

HA Vanderven, L Liu, F Ana-Sosa-Batiz, THO Nguyen, Y Wan, B Wines, P Mark Hogarth, D Tilmanis, A Reynaldi, MS Parsons, AC Hurt, MP Davenport, T Kotsimbos, AC Cheng, K Kedzierska, X Zhang, J Xu, SJ Kent

2017-07-06

BACKGROUND. Both seasonal and novel avian influenza viruses can result in severe infections requiring hospitalization. Anti-influe..

Effect of Combination Antiretroviral Therapy on HIV-1-specific Antibody-Dependent Cellular Cytotoxicity Responses in Subtype B- and Subtype C-Infected Cohorts

V Madhavi, A Kulkarni, A Shete, WS Lee, MR McLean, AB Kristensen, M Ghate, BD Wines, PM Hogarth, MS Parsons, A Kelleher, DA Cooper, J Amin, S Emery, M Thakar, SJ Kent

2017-07-01

Background: There is growing interest in immune therapies to clear the latent HIV-1 after combination antiretroviral therapy (cART..

Charge Has a Marked Influence on Hyperbranched Polymer Nanoparticle Association in Whole Human Blood

JJ Glass, L Chen, S Alcantara, EJ Crampin, KJ Thurecht, R De Rose, SJ Kent

2017-06-20

In this study, we synthesize charge-varied hyperbranched polymers (HBPs) and demonstrate surface charge as a key parameter directi..

Twist in the Tail: Escape from HIV Neutralising Antibodies at a Single Site Confers Broad Susceptibility to Others

AK Wheatley, SJ Kent

2016-10-01

Modeling of Experimental Data Supports HIV Reactivation from Latency after Treatment Interruption on Average Once Every 5–8 Days

M Pinkevych, SJ Kent, M Tolstrup, SR Lewin, DA Cooper, OS Søgaard, TA Rasmussen, AD Kelleher, D Cromer, MP Davenport

2016-08-01

Antibody responses with Fc-mediated functions after vaccination of HIV-infected subjects with trivalent influenza vaccine

AB Kristensen, WN Lay, F Ana-Sosa-Batiz, HA Vanderven, V Madhavi, KL Laurie, L Carolan, BD Wines, M Hogarth, AK Wheatley, SJ Kent

2016-06-01

This study seeks to assess the ability of seasonal trivalent inactivated influenza vaccine (TIV) to induce nonneutralizing antibod..

High fidelity simian immunodeficiency virus reverse transcriptase mutants have impaired replication in vitro and in vivo

SB Lloyd, M Lichtfuss, TH Amarasena, S Alcantara, R De Rose, G Tachedjian, H Alinejad-Rokny, V Venturi, MP Davenport, WR Winnall, SJ Kent

2016-05-01

The low fidelity of HIV replication facilitates immune and drug escape. Some reverse transcriptase (RT) inhibitor drug-resistance ..

HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days—Implications for HIV Remission

M Pinkevych, D Cromer, M Tolstrup, AJ Grimm, DA Cooper, SR Lewin, OS Søgaard, TA Rasmussen, SJ Kent, AD Kelleher, MP Davenport

2015-07-01

HIV infection can be effectively controlled by anti-retroviral therapy (ART) in most patients. However therapy must be continued f..

Simian immunodeficiency virus infection and immune responses in the pig-tailed macaque testis

WR Winnall, SB Lloyd, R De Rose, S Alcantara, TH Amarasena, MP Hedger, JE Girling, SJ Kent

2015-03-01

The testis is a site of immune privilege in rodents, and there is evidence that T cell responses are also suppressed in the primat..

The high cost of fidelity

SB Lloyd, SJ Kent, WR Winnall

2014-01-01

The notoriously low fidelity of HIV-1 replication is largely responsible for the virus's rapid mutation rate, facilitating escape ..

The maturation of antibody technology for the HIV epidemic

WR Winnall, MD Beasley, RJ Center, MS Parsons, BR Kiefel, SJ Kent

2014-01-01

Antibodies are one of our most useful biological tools. Indeed, improvements in antibody-based technologies have ushered in a new ..

Toward improved influenza vaccines

SJ Kent

2014-01-01

Characterisation of macaque testicular leucocyte populations and T-lymphocyte immunity

R De Rose, CS Fernandez, MP Hedger, SJ Kent, WR Winnall

2013-12-01

The rodent testis is well established as a site of immune privilege where both innate and acquired immune responses are suppressed..